Recent News

• 04.10.2025 - Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
• 04.10.2025 - Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
• 04.08.2025 - Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
• 04.08.2025 - Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
• 03.31.2025 - Q4 2024 Omeros Corporation Earnings Conference Call
• 03.31.2025 - Q4 2024 Omeros Corporation Earnings Conference Call
• 03.31.2025 - Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
• 03.31.2025 - Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
• 03.26.2025 - Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
• 03.26.2025 - Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Recent Filings

• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - 8-K Current report
• 03.31.2025 - EX-99.1 EX-99.1
• 02.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors